Alivus Life Sciences Ltd.
NSE: ALIVUS BSE: ALIVUS
Prev Close
921.9
Open Price
980
Volume
36,675
Today Low / High
937 / 980
52 WK Low / High
819 / 1251
Range
908 - 1,003
Prev Close
920.8
Open Price
935.15
Volume
1,632
Today Low / High
935.15 / 961.35
52 WK Low / High
827.1 / 1259.75
Range
904 - 999
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 955.55 (target range: 908 - 1,003), reflecting a change of 33.65 (3.65007%). On the BSE, it is listed at 951.35 (target range: 904 - 999), showing a change of 30.55 (3.31777%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Alivus Life Sciences Ltd. Graph
Alivus Life Sciences Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alivus Life Sciences Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 955.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 951.35 | 960.86 | 864.78 - 1,056.95 |
| 970.38 | 776.30 - 1,164.45 | ||
| 979.89 | 685.92 - 1,273.86 | ||
| Bearish Scenario | 951.35 | 941.84 | 847.65 - 1,036.02 |
| 932.32 | 745.86 - 1,118.79 | ||
| 922.81 | 645.97 - 1,199.65 |
Overview of Alivus Life Sciences Ltd.
ISIN
INE03Q201024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
95,181
Market Cap
117,225,153,600
Last Dividend
5
Official Website
IPO Date
2025-01-13
DCF Diff
240.94
DCF
681
Financial Ratios Every Investor Needs
Stock Dividend of ALIVUS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-01 | September 01, 25 | 5 | 5 | 2025-09-01 | 2025-09-12 | |
| 2023-10-17 | October 17, 23 | 22.5 | 22.5 | 2023-10-17 | 2023-11-08 | |
| 2023-03-24 | March 24, 23 | 21 | 21 | 2023-03-24 | 2023-03-29 | |
| 2022-09-15 | September 15, 22 | 10.5 | 10.5 | 2022-09-16 | 2022-10-26 | |
| 2021-11-22 | November 22, 21 | 10.5 | 10.5 | 2021-11-23 | 2021-12-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,371.89 Cr | 1,608.05 Cr | 763.85 Cr | 0.3220 | 0.00 Cr | 17.13 Cr | 623.80 Cr | 485.63 Cr | 39.63 | 717.15 Cr | 0.2047 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 71.06 Cr | 3,411.45 Cr | 594.08 Cr | 2,817.3720 Cr | 56.61 Cr | -14.46 Cr | 673.95 Cr | 1,045.72 Cr | 0.00 Cr | 0.00 Cr | 0.08 Cr | 470.1590 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 411.4200 Cr | -635.6580 Cr | -6.1140 Cr | 245.2330 Cr | -230.3520 Cr | 71.0620 Cr | -166.1870 Cr | 654.1310 Cr | 0.0000 Cr | 0.0000 Cr | -38.8550 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 587.98 Cr | 333.75 Cr | 254.23 Cr | 0.4324 | 160.74 Cr | 130.03 Cr | 10.60 | 193.89 Cr | 0.2211 |
| 2025-06-30 | 601.85 Cr | 270.39 Cr | 331.46 Cr | 0.5507 | 155.25 Cr | 121.54 Cr | 9.91 | 181.30 Cr | 0.2019 |
| 2025-03-31 | 602.50 Cr | 300.87 Cr | 301.63 Cr | 0.5006 | 184.28 Cr | 141.87 Cr | 0.00 | 208.52 Cr | 0.2355 |
| 2024-12-31 | 641.84 Cr | 285.27 Cr | 356.57 Cr | 0.5555 | 175.15 Cr | 136.96 Cr | 11.18 | 200.76 Cr | 0.2134 |
| 2024-09-30 | 506.88 Cr | 225.20 Cr | 281.68 Cr | 0.5557 | 119.27 Cr | 95.32 Cr | 7.78 | 142.89 Cr | 0.1880 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 19.18 Cr | 633.62 Cr | 652.80 Cr | 1,002.85 Cr | 722.51 Cr | 2,475.95 Cr | 1,122.13 Cr | 3,638.34 Cr | 622.99 Cr |
| 2025-03-31 | 71.06 Cr | 477.62 Cr | 548.68 Cr | 1,009.61 Cr | 673.95 Cr | 2,335.16 Cr | 1,045.72 Cr | 3,411.45 Cr | 594.08 Cr |
| 2024-09-30 | 446.12 Cr | 84.09 Cr | 530.20 Cr | 775.13 Cr | 689.20 Cr | 2,096.06 Cr | 945.12 Cr | 3,084.86 Cr | 546.38 Cr |
| 2024-03-31 | 301.41 Cr | 90.55 Cr | 301.41 Cr | 855.80 Cr | 666.59 Cr | 1,916.00 Cr | 904.78 Cr | 2,850.41 Cr | 518.09 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,697.80 | ₹4,073,590,912,066.00 | ₹3,930,868.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,290.00 | ₹1,669,797,368,200.00 | ₹244,814.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,033.60 | ₹1,365,153,526,784.00 | ₹240,277.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,231.80 | ₹1,025,557,496,442.00 | ₹761,638.00 |
| Lupin Limited | LUPIN | ₹2,190.80 | ₹1,000,755,249,200.00 | ₹367,005.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹906.80 | ₹912,452,982,132.00 | ₹347,388.00 |
| Mankind Pharma Limited | MANKIND | ₹2,159.30 | ₹891,369,991,970.00 | ₹116,092.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,236.30 | ₹718,045,046,515.00 | ₹1,217,552.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,698.00 | ₹681,281,370,000.00 | ₹69,308.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,979.40 | ₹558,588,281,335.00 | ₹233,253.00 |
| Laurus Labs Limited | LAURUSLABS | ₹980.35 | ₹529,248,400,164.00 | ₹951,956.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,443.40 | ₹366,196,668,261.00 | ₹54,740.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,837.00 | ₹354,442,365,288.00 | ₹25,237.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,894.10 | ₹303,879,933,500.00 | ₹86,928.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,503.70 | ₹285,060,228,398.00 | ₹62,288.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,349.00 | ₹219,201,935,981.00 | ₹408,785.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,649.50 | ₹216,237,500,000.00 | ₹2,110.00 |
| Eris Lifesciences Limited | ERIS | ₹1,428.20 | ₹194,544,963,726.00 | ₹13,251.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,435.00 | ₹172,369,558,715.00 | ₹18,003.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹988.90 | ₹156,611,843,797.00 | ₹50,041.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹793.40 | ₹155,953,182,582.00 | ₹14,005.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹853.00 | ₹152,780,719,110.00 | ₹355,318.00 |
| Cohance Lifesciences Limited | COHANCE | ₹386.60 | ₹147,900,456,324.00 | ₹145,589.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,836.00 | ₹139,557,473,856.00 | ₹30,496.00 |
| Granules India Limited | GRANULES | ₹569.30 | ₹138,151,300,019.00 | ₹257,455.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹955.05 | ₹117,219,016,800.00 | ₹36,675.00 |
| Viyash Scientific Limited | VIYASH | ₹216.91 | ₹94,617,347,803.00 | ₹984,027.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,288.50 | ₹87,785,831,707.00 | ₹10,667.00 |
| Strides Pharma Science Limited | STAR | ₹863.10 | ₹79,554,269,453.00 | ₹148,496.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹789.55 | ₹71,570,570,978.00 | ₹68,670.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹452.50 | ₹69,278,681,245.00 | ₹71,811.00 |
| FDC Limited | FDC | ₹381.20 | ₹62,063,204,021.00 | ₹23,733.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹299.85 | ₹58,645,207,528.00 | ₹235,068.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹144.94 | ₹47,036,158,965.00 | ₹2,957,569.00 |
| Innova Captab Limited | INNOVACAP | ₹723.15 | ₹41,382,207,406.00 | ₹38,298.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹399.00 | ₹36,416,730,000.00 | ₹111,236.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.40 | ₹35,566,262,496.00 | ₹17,410.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹685.00 | ₹34,742,586,925.00 | ₹32,360.00 |
| Suven Life Sciences Limited | SUVEN | ₹146.50 | ₹33,324,941,000.00 | ₹213,933.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,995.00 | ₹32,995,334,925.00 | ₹5,638.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹306.35 | ₹30,721,545,713.00 | ₹21,387.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹397.75 | ₹28,003,887,063.00 | ₹27,679.00 |
Key Executives
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born: 1965
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born:
FAQs about Alivus Life Sciences Ltd.
The CEO is Yasir Yusufali Rawjee.
The current price is ₹955.10.
The range is ₹819-1251.
The market capitalization is ₹11,722.52 crores.
The dividend yield is 0.52%.
The P/E ratio is 22.09.
The company operates in the Healthcare sector.
Overview of Alivus Life Sciences Ltd. (ISIN: INE03Q201024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹11,722.52 crores and an average daily volume of 95,181 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.